1
|
Li B, Barnhart RW, Dion A, Guinness S, Happe A, Hayward CM, Kohrt J, Makowski T, Maloney M, Nelson JD, Nematalla A, McWilliams JC, Peng Z, Raggon J, Sagal J, Weisenburger GA, Bao D, Gonzalez M, Lu J, McLaws MD, Tao J, Wu B. Process Development of a Second Generation β-Amyloid-Cleaving Enzyme Inhibitor—Improving the Robustness of a Halogen-Metal Exchange Using Continuous Stirred-Tank Reactors. Org Process Res Dev 2021. [DOI: 10.1021/acs.oprd.1c00126] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Bryan Li
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
- Chemical Research & Development La Jolla Laboratory, Worldwide Research Development & Medical, Pfizer Inc., Science Center Drive, San Diego, California 92121, United States
| | - Richard W. Barnhart
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Amelie Dion
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Steven Guinness
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Alan Happe
- Chemical Research & Development Worldwide Research Development & Medical, Pfizer Inc., Ramsgate Road, Sandwich CT13 9ND, U.K
| | - Cheryl M. Hayward
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jeffrey Kohrt
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Teresa Makowski
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Mark Maloney
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jade D. Nelson
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Asaad Nematalla
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - J. Christopher McWilliams
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Zhihui Peng
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jeffrey Raggon
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - John Sagal
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Gerald A. Weisenburger
- Chemical Research & Development, Worldwide Research Development & Medical, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Denghui Bao
- Asymchem Life Science Co. Limited, No. 71, 7th Street, TEDA, Tianjin 300457, China
| | - Miguel Gonzalez
- Asymchem Life Science Co. Limited, No. 71, 7th Street, TEDA, Tianjin 300457, China
| | - Jiangping Lu
- Asymchem Life Science Co. Limited, No. 71, 7th Street, TEDA, Tianjin 300457, China
| | - Mark D. McLaws
- Asymchem Life Science Co. Limited, No. 71, 7th Street, TEDA, Tianjin 300457, China
| | - Jian Tao
- Asymchem Life Science Co. Limited, No. 71, 7th Street, TEDA, Tianjin 300457, China
| | - Baolin Wu
- Asymchem Life Science Co. Limited, No. 71, 7th Street, TEDA, Tianjin 300457, China
| |
Collapse
|
2
|
Zhao J, Liu X, Xia W, Zhang Y, Wang C. Targeting Amyloidogenic Processing of APP in Alzheimer's Disease. Front Mol Neurosci 2020; 13:137. [PMID: 32848600 PMCID: PMC7418514 DOI: 10.3389/fnmol.2020.00137] [Citation(s) in RCA: 68] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Accepted: 07/08/2020] [Indexed: 12/11/2022] Open
Abstract
Alzheimer's disease (AD) is the most common type of senile dementia, characterized by neurofibrillary tangle and amyloid plaque in brain pathology. Major efforts in AD drug were devoted to the interference with the production and accumulation of amyloid-β peptide (Aβ), which plays a causal role in the pathogenesis of AD. Aβ is generated from amyloid precursor protein (APP), by consecutive cleavage by β-secretase and γ-secretase. Therefore, β-secretase and γ-secretase inhibition have been the focus for AD drug discovery efforts for amyloid reduction. Here, we review β-secretase inhibitors and γ-secretase inhibitors/modulators, and their efficacies in clinical trials. In addition, we discussed the novel concept of specifically targeting the γ-secretase substrate APP. Targeting amyloidogenic processing of APP is still a fundamentally sound strategy to develop disease-modifying AD therapies and recent advance in γ-secretase/APP complex structure provides new opportunities in designing selective inhibitors/modulators for AD.
Collapse
Affiliation(s)
- Jing Zhao
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States
| | - Xinyue Liu
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States
| | - Weiming Xia
- Geriatric Research Education Clinical Center, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, United States
- Department of Pharmacology and Experimental Therapeutics, School of Medicine, Boston University, Boston, MA, United States
| | - Yingkai Zhang
- Department of Chemistry, New York University, New York, NY, United States
| | - Chunyu Wang
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States
- Department of Biological Sciences, Rensselaer Polytechnic Institute, Troy, NY, United States
- Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY, United States
| |
Collapse
|
3
|
Garcia-Losada P, DeBaillie AC, Eugenio de Diego J, Green SJ, Hansen MM, Jaramillo C, Johnson M, Kaoudi T, Li J, Lindsay-Scott PJ, Mateos C, Mergott DJ, Rincon JA, Rothhaar RR, Seibert KD, Watson BM, Winneroski LL, Gangula S, Jing D, Sun H, Zhang L, Frederick MO. Synthesis, Optimization, and Large-Scale Preparation of the Low-Dose Central Nervous System-Penetrant BACE1 Inhibitor LY3202626 via a [3 + 2] Nitrone Cycloaddition. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.9b00471] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Pablo Garcia-Losada
- Centro de Investigación Lilly S.A., Avda. de la Industria 30, Alcobendas-Madrid 28108, Spain
| | - Amy C. DeBaillie
- Small Molecule Design and Development, Eli Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States
| | - Jose Eugenio de Diego
- Centro de Investigación Lilly S.A., Avda. de la Industria 30, Alcobendas-Madrid 28108, Spain
| | - Steven J. Green
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Marvin M. Hansen
- Small Molecule Design and Development, Eli Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States
| | - Carlos Jaramillo
- Centro de Investigación Lilly S.A., Avda. de la Industria 30, Alcobendas-Madrid 28108, Spain
| | - Matt Johnson
- Asymchem Life Science (Tianjin) Co., Ltd., 71 Seventh Avenue, TEDA, Tianjin 300457, P. R. China
| | - Talbi Kaoudi
- Centro de Investigación Lilly S.A., Avda. de la Industria 30, Alcobendas-Madrid 28108, Spain
| | - Jiuyuan Li
- Asymchem Life Science (Tianjin) Co., Ltd., 71 Seventh Avenue, TEDA, Tianjin 300457, P. R. China
| | - Peter J. Lindsay-Scott
- Lilly Research Laboratories, Erl Wood Manor, Windlesham, Surrey GU20 6PH, United Kingdom
| | - Carlos Mateos
- Centro de Investigación Lilly S.A., Avda. de la Industria 30, Alcobendas-Madrid 28108, Spain
| | - Dustin J. Mergott
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Juan Antonio Rincon
- Centro de Investigación Lilly S.A., Avda. de la Industria 30, Alcobendas-Madrid 28108, Spain
| | - Roger R. Rothhaar
- Small Molecule Design and Development, Eli Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States
| | - Kevin D. Seibert
- Small Molecule Design and Development, Eli Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States
| | - Brian M. Watson
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Leonard L. Winneroski
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Srinivas Gangula
- Asymchem Life Science (Tianjin) Co., Ltd., 71 Seventh Avenue, TEDA, Tianjin 300457, P. R. China
| | - Dajiang Jing
- Asymchem Life Science (Tianjin) Co., Ltd., 71 Seventh Avenue, TEDA, Tianjin 300457, P. R. China
| | - Hao Sun
- Asymchem Life Science (Tianjin) Co., Ltd., 71 Seventh Avenue, TEDA, Tianjin 300457, P. R. China
| | - Lei Zhang
- Asymchem Life Science (Tianjin) Co., Ltd., 71 Seventh Avenue, TEDA, Tianjin 300457, P. R. China
| | - Michael O. Frederick
- Small Molecule Design and Development, Eli Lilly and Company, Lilly Corporate
Center, Indianapolis, Indiana 46285, United States
| |
Collapse
|
4
|
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints. Bioorg Med Chem 2020; 28:115194. [DOI: 10.1016/j.bmc.2019.115194] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Revised: 10/25/2019] [Accepted: 10/29/2019] [Indexed: 12/17/2022]
|
5
|
Mennen SM, Alhambra C, Allen CL, Barberis M, Berritt S, Brandt TA, Campbell AD, Castañón J, Cherney AH, Christensen M, Damon DB, Eugenio de Diego J, García-Cerrada S, García-Losada P, Haro R, Janey J, Leitch DC, Li L, Liu F, Lobben PC, MacMillan DWC, Magano J, McInturff E, Monfette S, Post RJ, Schultz D, Sitter BJ, Stevens JM, Strambeanu II, Twilton J, Wang K, Zajac MA. The Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00140] [Citation(s) in RCA: 148] [Impact Index Per Article: 29.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Steven M. Mennen
- Drug Substance Technologies, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Carolina Alhambra
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - C. Liana Allen
- API Chemistry, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Mario Barberis
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Simon Berritt
- Internal Medicine, Applied Synthesis Technology, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Thomas A. Brandt
- Process Chemistry, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Andrew D. Campbell
- Pharmaceutical Technology and Development, AstraZeneca, Silk Road Business Park, Macclesfield, Cheshire SK10 2NA, United Kingdom
| | - Jesús Castañón
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Alan H. Cherney
- Drug Substance Technologies, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Melodie Christensen
- Process Research and Development, Merck & Co., Inc. Rahway, New Jersey 07065, United States
| | - David B. Damon
- Process Chemistry, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - J. Eugenio de Diego
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Susana García-Cerrada
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Pablo García-Losada
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Rubén Haro
- Centro de Investigación Lilly S. A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Jacob Janey
- Chemical and Synthetic Development, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - David C. Leitch
- API Chemistry, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Ling Li
- API Chemistry, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Fangfang Liu
- Pharmaceutical Sciences, Pfizer Global Supply Statistics, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Paul C. Lobben
- Chemical and Synthetic Development, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - David W. C. MacMillan
- Merck Center for Catalysis at Princeton University, Washington Road, Princeton, New Jersey 08544, United States
| | - Javier Magano
- Process Chemistry, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Emma McInturff
- Process Chemistry, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Sebastien Monfette
- Process Chemistry, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Ronald J. Post
- Engineering Group, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Danielle Schultz
- Process Research and Development, Merck & Co., Inc. Rahway, New Jersey 07065, United States
| | - Barbara J. Sitter
- Process Chemistry, Chemical R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jason M. Stevens
- Chemical and Synthetic Development, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States
| | - Iulia I. Strambeanu
- API Chemistry, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Jack Twilton
- Merck Center for Catalysis at Princeton University, Washington Road, Princeton, New Jersey 08544, United States
| | - Ke Wang
- Pharmaceutical Sciences, Pfizer Global Supply Statistics, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Matthew A. Zajac
- API Chemistry, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| |
Collapse
|
6
|
Garcia-Losada P, Barberis M, Shi Y, Hembre E, Alhambra Jimenez C, Winneroski LL, Watson BM, Jones C, DeBaillie AC, Martínez-Olid F, Mergott DJ. Practical Asymmetric Fluorination Approach to the Scalable Synthesis of New Fluoroaminothiazine BACE Inhibitors. Org Process Res Dev 2018. [DOI: 10.1021/acs.oprd.8b00069] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Pablo Garcia-Losada
- Centro de Investigación Lilly S.A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Mario Barberis
- Centro de Investigación Lilly S.A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Yuan Shi
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Erik Hembre
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | | | - Leonard L. Winneroski
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Brian M. Watson
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Chauncey Jones
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Amy C. DeBaillie
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Francisco Martínez-Olid
- Centro de Investigación Lilly S.A., Avda. de la Industria 30, Alcobendas, Madrid 28108, Spain
| | - Dustin J. Mergott
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| |
Collapse
|
7
|
Thaisrivongs DA, Naber JR, Rogus NJ, Spencer G. Development of an Organometallic Flow Chemistry Reaction at Pilot-Plant Scale for the Manufacture of Verubecestat. Org Process Res Dev 2018. [DOI: 10.1021/acs.oprd.7b00385] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- David A. Thaisrivongs
- Process Research and Development, Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
| | - John R. Naber
- Process Research and Development, Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
| | - Nicholas J. Rogus
- Process Research and Development, Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
| | - Glenn Spencer
- Process Research and Development, Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065, United States
| |
Collapse
|
8
|
DeBaillie AC, Jasper PJ, Li S, McCulley MJ, Vaidyaraman S, Zhang Z. Optimization of an Aminothiazine Ring Formation: Integrating Modeling with Experiments to Maximize Yield by Minimizing Impurity Formation. Org Process Res Dev 2015. [DOI: 10.1021/acs.oprd.5b00036] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Amy C. DeBaillie
- Eli Lilly and
Company, Small Molecule Design and Development, Indianapolis, Indiana 46285, United States
| | - Paul J. Jasper
- RES Group, Inc. 75 Second Avenue, Needham, Massachusetts 02494, United States
| | - Su Li
- RES Group, Inc. 75 Second Avenue, Needham, Massachusetts 02494, United States
| | - Michael J. McCulley
- Eli Lilly and
Company, Small Molecule Design and Development, Indianapolis, Indiana 46285, United States
| | - Shankar Vaidyaraman
- Eli Lilly and
Company, Small Molecule Design and Development, Indianapolis, Indiana 46285, United States
| | - Zhiwei Zhang
- RES Group, Inc. 75 Second Avenue, Needham, Massachusetts 02494, United States
| |
Collapse
|
9
|
Hansen MM, Jarmer DJ, Arslantas E, DeBaillie AC, Frederick AL, Harding M, Hoard DW, Hollister A, Huber D, Kolis SP, Kuehne-Willmore JE, Kull T, Laurila ME, Linder RJ, Martin TJ, Martinelli JR, McCulley MJ, Richey RN, Starkey DR, Ward JA, Zaborenko N, Zweifel T. Synthesis of BACE Inhibitor LY2886721. Part II. Isoxazolidines as Precursors to Chiral Aminothiazines, Selective Peptide Coupling, and a Controlled Reactive Crystallization. Org Process Res Dev 2015. [DOI: 10.1021/op500327t] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Marvin M. Hansen
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Daniel J. Jarmer
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Enver Arslantas
- Dottikon
Exclusive
Synthesis AG, P.O. Box 5605, Dottikon, Switzerland
| | - Amy C. DeBaillie
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Andrea L. Frederick
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Molly Harding
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - David W. Hoard
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Adrienne Hollister
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Dominique Huber
- Dottikon
Exclusive
Synthesis AG, P.O. Box 5605, Dottikon, Switzerland
| | - Stanley P. Kolis
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Jennifer E. Kuehne-Willmore
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Thomas Kull
- Dottikon
Exclusive
Synthesis AG, P.O. Box 5605, Dottikon, Switzerland
| | - Michael E. Laurila
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Ryan J. Linder
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Thomas J. Martin
- Dottikon
Exclusive
Synthesis AG, P.O. Box 5605, Dottikon, Switzerland
| | - Joseph R. Martinelli
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Michael J. McCulley
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Rachel N. Richey
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Derek R. Starkey
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Jeffrey A. Ward
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Nikolay Zaborenko
- Small
Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Theo Zweifel
- Dottikon
Exclusive
Synthesis AG, P.O. Box 5605, Dottikon, Switzerland
| |
Collapse
|